ADVANCED COURSES & SEMINARS
*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.
Chairs: J.Y Blay, FR - P.G. Casali, IT - R. Stahel, CH
Rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. This Course is aimed at dealing with them on an annual basis with the ultimate goal to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence. This course has been conceived in the context of the European Reference Network on Rare Adult Solid Cancers (EURACAN) and the Joint Action on Rare Cancers of the European Union (JARC). The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with the networking activities of EURACAN and the networking educational efforts that are ongoing within EURACAN, JARC and Rare Cancers Europe.
The RARECARE project provided a definition and a list of rare cancers, the following being the 10 “families” of rare adult solid cancers:
• Rare skin cancers and non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head and neck cancers
The third edition of this joint initiative, which involves ESO, ESMO and Rare Cancers Europe, will combine:
• Day 1 - Parallel Preceptorships on the majority of rare adult solid cancers. Participants will be invited to select 3 preceptorships they would like to attend.
• Day 2 and 3 - Clinical updates on the main innovations from the 10 families of rare adult solid cancers.
Preceptorships have been conceived by looking at the educational needs of clinical oncologists willing to open up to rare adult solid cancers as well as patient advocates. They will be multidisciplinary and clinically oriented.
The Clinical update sessions are designed to address the needs of oncologists wanting to catch up with the advancements in the treatment of rare adult solid cancers.
Attendees may select whether to attend all three days or only the 2-day Clinical Update.
|The course is an ESO-ESMO-RCE joint event|
|Held in collaboration with||In the framework of|
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y. Blay, Centre Léon Bérard, Lyon, FR
A. Berruti, ASST Spedali Civili, Brescia, IT
J. Capdevila, Vall d'Hebron University Hospital, Barcelona, ES
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
F. De Lorenzo, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.G. Eriksen, Aarhus University Hospital, Aarhus, DK
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Girard, Hopital Louis Pradel, Bron, FR
J.A. Gietema, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R. Labianca, ASST Papa Giovanni XXIII, Bergamo IT
C. Lebbé, Hopital St. Louis, Paris, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
D. Lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
V. Mazzaferro, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Niger, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
U. Pastorino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. Peccatori, European School of Oncology, Milan, IT
F. Raspagliesi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
J. Sacco, The Clatterbridge Cancer Centre, Liverpool, UK
M. Seckl, Hammersmith Campus, London, UK
C. Simon, Université de Lausanne, CHUV Lausanne, CH
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
D. Talbot, Oxford University Hospital, Oxford, UK
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Van den Bent, Erasmus MC Cancer Institute, Rotterdam, NL
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
MZ Congressi S.r.l.
Via Carlo Farini, 81
Fondazione Cariplo Conference Center
Via Romagnosi, 8
The course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 19 European CME credits (ECMEC®s).
Application for CME recognition has been submitted to the Italian CME accreditation system. Learning objectives: application of the principles of evidence based practice (EBM - EBN - EBP) in the daily routine.
The badge is the only official evidence of registration and should be worn at all times during the event.
The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance.
The official language will be English. No translation will be provided.
ESO wishes to express its gratitude to Fondazione Cariplo - Iniziative Patrimoniali S.p.A. for their support in hosting the course in its premises.
and to Eisai and PharmaMar for their unrestricted educational grants.
|Late registration from:||01 November 2018|
|Save the event date:||01 December 2018|
• Medical degree
• Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
• Fluency in English
The online registration at the top of the page is related ONLY to the three-day course.
If interested in participating in the Clinical Update course only (2 days), please refer to this link for online registration.
Registration to the full course (3 days) should be completed by sending the preceptorship form (downloadable HERE) to firstname.lastname@example.org immediately after online registration.
PATIENT ADVOCATES will be selected by Rare Cancers Europe. For information email@example.com
(From 1 November)
|Registration fee (full participation rate - 3 days)
|| EUR 250
|| EUR 300
|Club ESO and ESMO Members (full participation rate)|| EUR 200
|Registration fee (Clinical Update - 2nd and 3rd day)||EUR 200||EUR 250
|Club ESO and ESMO Members (Clinical update)|| EUR 160
Rates are indicated in Euro and include VAT.
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.
CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee minus handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by ESO before 9 November. Communication of replacements will be possible up until 15 November.
PRECEPTORSHIPS ON RARE ADULT SOLID CANCERS
|8:30||Registration and coffee entry
P.G. Casali, IT
|9:00||Epidemiology and rare cancer networking
A. Trama, IT
|9:30||The pathologic diagnosis
A.P. Dei Tos, IT
|10:00||Clinical decision making in RC
P.G. Casali, IT
|BREAKOUT PRECEPTORSHIP 1|
S. Bielack, GR - J.Y. Blay, FR - P.G. Casali, IT - A. Gronchi, IT
|11:00||Rare urogenital cancers
J.A. Gietema, NL - N. Nicolai, IT
|11:00||Digestive rare cancers
V. Mazzaferro, IT - R. Glynne-Jones, UK - M. Niger, IT
|BREAKOUT PRECEPTORSHIP 2|
D. Talbot, UK - V. Mazzaferro, IT
|14:00||Rare thoracic cancers
R.A. Stahel, CH - M. Garassino, IT - N. Girard, FR - U. Pastorino, IT
|14:00||Rare skin tumors and uveal melanoma
C. Lebbé, FR - L. Licitra, IT - M. Angi, IT - J. Sacco, UK
|BREAKOUT PRECEPTORSHIP 3|
R. Soffietti, IT - M. van den Bent, NL
|16:30||Rare female genital cancers
D. Lorusso, IT - I. Ray-Coquard, FR - F. Raspagliesi, IT - M. Seckl, UK
|16:30||Head and neck cancers w/ Thyroid cancer
K. Newbold, UK - J. Capdevila, ES - C. Simon, CH - L. Licitra, IT
CLINICAL UPDATE on RARE ADULT SOLID CANCERS
|9:00||Welcome from ESO and ESMO
F. Peccatori IT - R.A. Stahel, CH
|UPDATE ON RARE THORACIC CANCERS
Moderators: M. Garassino IT, RA Stahel CH
R.A. Stahel, CH
N. Girard, FR
|UPDATE ON RARE FEMALE GENITAL CANCERS
Moderators: D. Lorusso, IT - F. Peccatori, IT
|10:10||Non-epithelial ovarian tumors
I. Ray-Coquard, FR
M. Seckl, UK
|UPDATE ON DIGESTIVE RARE CANCERS
Moderators: R. Labianca, IT - V. Mazzaferro, IT
F. de Braud, IT
R. Glynne-Jones, UK
|12:20||Peritoneal mesothelioma & pseudomyxoma peritonei
M. Deraco, IT
|UPDATE ON CNS TUMORS
Moderators: R. Soffietti, IT - M. van den Bent, NL
R. Soffietti, IT
|14:20||Rare CNS tumors
M. van den Bent, NL
|UPDATE ON SARCOMAs
Moderators: P.G. Casali, IT - A. Gronchi, IT
|15:00||Adult soft tissue sarcomas
P.G. Casali, IT
J.Y. Blay, FR
|15:40||Ewing sarcoma and Osteosarcoma
S. Bielack, DE
|16:00||Rare bone sarcomas
S. Stacchiotti, IT
|UPDATE ON RARE UROGENITAL CANCERS
Moderators: J.A. Gietema, NL - N. Nicolai, IT
J.A. Gietema, NL
|UPDATE ON NEUROENDOCRINE TUMORS
Moderators: D. Talbot, UK - F. De Braud IT
|17:30||Thoracic neuroendocrine tumors
D. Talbot, UK
|17:50||Gastroenteropancreatic neuroendocrine tumors
N. Fazio, IT
|UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA
Moderators: M. Angi, IT - C. Lebbé, FR
M. Angi, IT
|9:20||Merkel cell carcinoma
C. Lebbé, FR
|UPDATE ON HEAD & NECK CANCERS
Moderators: J.G. Eriksen, DK - L. Licitra, IT
|10:00||Laryngeal & hypopharyngeal carcinoma
L. Licitra, IT
J.G. Eriksen, DK
|11:00||Nasopharyngeal carcinoma & sinonasal cancers
L. Licitra, IT
|11:20||Salivary gland tumors
L. Licitra, IT
|UPDATE ON ENDOCRINE GLAND TUMORS
Moderator: L. Licitra, IT
J. Capdevila, ES
A. Berruti, IT
|14:00||Round table: Rare cancers in Europe (plenary)
P.G. Casali, IT - D. De Lorenzo, BE - A. Trama, IT
|15:30||Closing remarks, with a view to networking…
P.G. Casali, IT
Patient Advocates Training Course
RCE-ESMO-ESO TRAINING COURSE FOR RARE CANCER PATIENT ADVOCATES
1-3 December 2018 - Milan, Italy
From 1-3 December 2018, RCE-ESMO-ESO are organising a specific training course for rare cancer patient advocates. The 2018 edition of the event will bring together patient advocates from across Europe, to exchange views and ideas with clinicians and researchers, who are attending the parallel ESO-ESMO-RCE Preceptorships and Clinical Update on Rare Adult Solid Cancers.
The draft agenda is available HERE.
For further information please visit the RCE website.